An international research team, led by Icahn School of Medicine at Mount Sinai investigators, designed and tested a high-density lipoprotein (HDL) nanoparticle loaded with a statin drug. In mouse studies, they show HDL nanotherapy is capable of directly targeting and lowering dangerous inflammation in blood vessels.